Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. (Q48334990)

10 February 2018

title

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. (English)

1 reference

10 February 2018

author

Nelson Leung

15

1 reference

10 February 2018

Robert A Kyle

14

R A Kyle

1 reference

10 February 2018

20

S V Rajkumar

1 reference

10 February 2018

Morie A Gertz

4

M A Gertz

1 reference

10 February 2018

John A. Lust

17

J A Lust

1 reference

10 February 2018

Martha Q Lacy

6

M Q Lacy

1 reference

10 February 2018

Angela Dispenzieri

3

A Dispenzieri

1 reference

10 February 2018

Francis K Buadi

5

F K Buadi

1 reference

10 February 2018

Ronald S Go

16

R S Go

1 reference

10 February 2018

David Dingli

7

D Dingli

1 reference

10 February 2018

Wilson I Gonsalves

11

W I Gonsalves

1 reference

10 February 2018

Miriam A Hobbs

10

M A Hobbs

1 reference

10 February 2018

author name string

S Sidana

1

1 reference

10 February 2018

N Tandon

2

1 reference

10 February 2018

A L Fonder

8

1 reference

10 February 2018

S R Hayman

9

1 reference

10 February 2018

Y L Hwa

12

1 reference

10 February 2018

P Kapoor

13

1 reference

10 February 2018

S J Russell

18

1 reference

10 February 2018

S R Zeldenrust

19

1 reference

10 February 2018

S K Kumar

21

1 reference

10 February 2018

publication date

18 September 2017

1 reference

10 February 2018

published in

Leukemia

1 reference

10 February 2018

https://scigraph.springernature.com/pub.10.1038/leu.2017.286

exact match

0 references

cites work

Amyloidosis: pathogenesis and new therapeutic options.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.286

inferred from DOI database lookup

7 January 2021

based on heuristic

Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28919633

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28919633

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2017.286

1 reference

10 February 2018

PubMed ID

28919633

1 reference

10 February 2018